LGND's partners and collaborators (LLY, GLX, Dana Farber Institute at Harvard) will also be presenting at an upcoming diabetes conference. Here's what GLX has to say about rexinoid agonists (like Targretin. LGD1268, or LGD1324):
Regulation of Adipocyte Metabolism using Multiple Insulin
Sensitizers: A Role for PPARg, RXR and b-3 Adrenoreceptor
Agonists for Treating NIDDM
James M. Lenhard, Ph.D., Research Investigator II, Metabolic
Diseases, Glaxo Wellcome
Given the pleiotropic nature of diabetes, multiple agents are needed to
treat the disease. We show antidiabetic PPARg and RXR agonists act
synergistically to increase adipocyte differentiation and
b3g-adrenoreceptor mediated lipolysis in vitro. In vivo, these agents
improved glycemic control in diabetic mice suffering from pancreatic islet
degeneration. Although PPARg agonists were more effective at
decreasing serum lipids and preventing diabetic cachexia, the RXR
agonists were more effective at causing hepatotomigaly in mice. In
combination, PPARg agonists improved the antidiabetic efficacy of RXR
agonists. Furthermore, PPARg agonists increased b3-adrenoreceptor
mediated thermogenesis in these mice, which may explain the
antidiabetic effect of these agents |
